MedTrace Logo

Effector and Memory Immune Responses to HPV Vaccination in Vietnamese Women Post Virus Exposure

NCT06681636 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2024-11-08

No results posted yet for this study

Summary

A Study to evaluate if the 3 dose extended schedule (0-6-18 months) for the HPV vaccine Gardasil-9 provide similar immune responses and short term protection against HPV infection compared to the regular 3 dose schedule (0-2-6 months) in high risk women in Vietnam

Conditions

Interventions

BIOLOGICAL

Human papillomavirus 9-valent vaccine, Recombinant

HPV vaccine manufactured by MSD consisted of 9HPV types: 6,11,16,18,31,33, 45, 52,58

Sponsors & Collaborators

  • Murdoch Childrens Research Institute

    collaborator OTHER

  • CENTER FOR SUPPORTING COMMUNITY DEVELOPMENT INITIATIVES

    collaborator UNKNOWN

  • Hai Phong Center for Disease Control

    collaborator OTHER_GOV

  • National Institute of Hygiene and Epidemiology, Vietnam

    lead OTHER

Principal Investigators

  • Hong T Duong, MD, PhD · National Institute of Hygiene and Epidemiology, Vietnam

  • Trang V Nguyen, PhD · National Institute of Hygiene and Epidemiology, Vietnam

  • Tuan A Le, MD, PhD · National Institute of Hygiene and Epidemiology, Vietnam

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
26 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-12-14
Primary Completion
2026-10-31
Completion
2027-12-31

Countries

  • Australia
  • Vietnam

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06681636 on ClinicalTrials.gov